New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
10:03 EDTATR, TEN, SFUN, MRVL, MRO, IPSEY, FNSR, CSH, CCG, BLL, LULUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AptarGroup (ATR) downgraded to Underperform from Neutral at BofA/Merrill... Ball Corp. (BLL) downgraded to Neutral from Buy at BofA/Merrill... Campus Crest (CCG) downgraded to Underperform from Neutral at BofA/Merrill... Cash America (CSH) downgraded to Market Perform at FBR Capital... Finisar (FNSR) downgraded to Hold from Buy at Craig-Hallum... Ipsen (IPSEY) downgraded to Neutral from Overweight at JPMorgan... Marathon Oil (MRO) downgraded to Market Perform from Outperform at Wells Fargo... Marvell (MRVL) downgraded at Susquehanna... Rackspace (RAX) downgraded to Underperform from Neutral at DA Davidson... SouFun (SFUN) downgraded to Neutral from Overweight at JPMorgan... Tenneco (TEN) downgraded to Hold from Buy at Deutsche Bank... lululemon (LULU) downgraded to Neutral from Overweight at JPMorgan.
News For ATR;BLL;CCG;CSH;FNSR;IPSEY;MRO;MRVL;SFUN;TEN;LULU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
08:21 EDTTENTenneco shares could rise 20%, says Wells Fargo
After Tenneco provided lower than expected Q4 commercial vehicle revenue guidance, Wells Fargo was surprised by the magnitude of the stock's decline and thinks the guidance was not as bad as it looks. The firm believes that the stock can rise 20% over the next few quarters and keeps an Outperform rating on the shares.
07:20 EDTTENTenneco sell-off a buying opportunity, says UBS
Subscribe for More Information
October 27, 2014
07:38 EDTTENTenneco sees 4Q14 revenue the same or slightly higher vs. 4Q13
Subscribe for More Information
07:32 EDTTENTenneco expects to finish FY14 with "strong revenue growth" YOY
Subscribe for More Information
07:31 EDTTENTenneco reports Q3 adjusted EPS $1.25, may not compare to consensus $1.08
Reports Q3 revenue $2.08B, consensus $2.08B.
October 24, 2014
10:03 EDTMROOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:08 EDTMROMarathon Oil initiated with a Buy at Mizuho
Subscribe for More Information
October 23, 2014
06:28 EDTCSHCash America: Growth largely associated with customer demand for credit products
Management believes that the opportunities for growth in revenue and earnings will be largely associated with customer demand for the credit products provided by the company, which take the form of pawn loans and consumer loans and the disposition of unredeemed collateral by way of consumer spending on retail sales and the commercial sale of refined gold and diamonds. The fourth quarter, during the seasonally important holiday selling season, represents an important period of retail sales for the company, and results will be affected by consumer sentiments during the period. There are various other elements that could affect the growth in revenue, such as the regulation of consumer loan products and the development and growth of additional markets for the company’s e-commerce segment for consumer lending products. As the company enters the fourth quarter of 2014, management anticipates that demand for the company’s consumer loan products will continue on a similar pace to the one it has experienced during the first nine months of 2014, with a continued heavier weighting to the consumer loan portfolio and longer-term installment and line of credit products. Demand for the Company’s pawn lending products during the second and third quarters of 2014 have improved, and management expects a continued growth in the Company’s pawn lending business, but at moderate levels for the balance of 2014 and the first half of 2015.
06:16 EDTCSHCash America sees FY15 adjusted EBITDA $110M-$135M for retali services
Subscribe for More Information
06:15 EDTCSHCash America sees FY14 adjusted EPS $4.40-$4.50, consensus $4.34
Management expects its consolidated fiscal year 2014 earnings per share to be in a range of between $4.40 and $4.50 per share as if the separation of the e-commerce business does not occur before year end 2014.
06:14 EDTCSHCash America sees Q4 EPS $1.00-$1.10, consensus 97c
Management is providing its expectations for the fourth quarter of 2014 as if the separation of the e-commerce segment, or Enova, does not occur before year-end 2014 in order to remain consistent with past practice related to reporting management’s expectations for future periods.
06:13 EDTCSHCash America reports Q3 EPS 82c, consensus 77c
Subscribe for More Information
October 22, 2014
16:48 EDTCSHCash America board approves spin-off of Enova International
Subscribe for More Information
15:27 EDTLULUlululemon management to meet with William Blair
Subscribe for More Information
10:03 EDTMRVLThe Linley Group to hold a conference
Subscribe for More Information
06:37 EDTCSHStates relax personal loan restrictions, NY Times says
Subscribe for More Information
05:17 EDTIPSEYIpsen, Lexicon enter into ex-North America/Japan licensing agreement
Ipsen (IPSEY) and Lexicon Pharmaceuticals (LXRX) announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan. Lexicon is conducting Phase 3 clinical trials of telotristat etiprate for carcinoid syndrome, a serious condition caused by symptomatic neuroendocrine tumors, which produce large amounts of serotonin. Carcinoid syndrome is characterized by severe diarrhea, flushing and, in some cases, heart valve damage. Telotristat etiprate is an oral, small-molecule inhibitor of tryptophan hydroxylase, or TPH, that reduces peripheral serotonin production without affecting brain serotonin levels. Telotristat etiprate has received fast track status and orphan drug designation from the FDA, and has received orphan drug designation from the European Medicines Agency. Under the financial terms of the agreement, Lexicon is eligible to receive up to $145M, comprising $23M upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones. In addition, Lexicon is also eligible to receive royalties on net sales of telotristat etiprate in the licensed territory.
04:57 EDTLULUlululemon partners with Dalai Lama Center
Subscribe for More Information
October 21, 2014
10:00 EDTTENOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:27 EDTTENTenneco initiated with a Positive at Susquehanna
Target $61.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use